Phase 2Completed
A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment
- Sponsor
- Egalet Ltd (Industry)
- Enrollment
- 36 enrolled
- Conditions
- Pain; Cancer
- Interventions
- Morphine Sulphate
- Ages
- adults, older adults
- Registry
- NCT00446069, EUCTR2006-006579-19
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.
Primary outcomes
- Use of rescue medication
History
Last registry update
Study completion
Primary completion
Started
Registered